NYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $13.90 -0.01 (-0.04%) As of 11:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Organon & Co. Stock (NYSE:OGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Organon & Co. alerts:Sign Up Key Stats Today's Range$13.89▼$13.9050-Day Range$13.65▼$13.9052-Week Range$5.69▼$13.90Volume220,972 shsAverage Volume4.92 million shsMarket Capitalization$3.65 billionP/E Ratio18.28Dividend Yield0.58%Price Target$12.00Consensus RatingReduce Company Overview Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology. Organon was formed as a spin-off from Merck & Co. in 2021 and is headquartered in Jersey City, New Jersey. It serves markets around the world through its international operations.AI Generated. May Contain Errors. Read More Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreOGN MarketRank™: 1.53810835629 of 5 starsOrganon & Co. scored higher than 31% of companies evaluated by MarketBeat, and ranked 774th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingReduce Consensus RatingOrganon & Co. has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Downside RiskOrganon & Co. has a consensus price target of $12.00, representing about 13.6% downside from its current price of $13.90.Amount of Analyst CoverageOrganon & Co. has only been the subject of 1 research reports in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.86% Earnings GrowthEarnings for Organon & Co. are expected to grow by 5.86% in the coming year, from $3.24 to $3.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 18.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 18.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.41.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOrganon & Co. has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.62% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 8.48.Change versus previous monthShort interest in Organon & Co. has recently increased by 4.66%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOrganon & Co. has a dividend yield of 0.58%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 10.53%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.33% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. News and Social Media3.4 / 5News Sentiment0.51 News SentimentOrganon & Co. has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Organon & Co. this week, compared to 2 articles on an average week.Search Interest6 people have searched for OGN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have not sold or bought any company stock.Percentage Held by Insiders1.62% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGN Stock News HeadlinesOrganon & Co. (NYSE:OGN) Stock Has Consensus Target Price of $11.40November 12 at 3:28 AM | americanbankingnews.comOrganon & Co. (OGN) Expected to Release Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.November 13 at 1:00 AM | Crypto 101 Media (Ad)New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across ...November 7, 2026 | marketscreener.comMOrganon & Co Ordinary Shares OGNNovember 3, 2026 | morningstar.comMReviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Organon & Co. (NYSE:OGN)November 2, 2026 | americanbankingnews.comOrganon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 31, 2026 | marketscreener.comMOrganon Highlights Non-GAAP Metrics Amid Pending MergerOctober 30, 2026 | tipranks.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $7.17 on January 1st, 2026. Since then, OGN shares have increased by 93.8% and is now trading at $13.8950. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) posted its quarterly earnings results on Friday, October, 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.06. The firm earned $1.57 billion during the quarter, compared to analysts' expectations of $1.58 billion. Organon & Co. had a trailing twelve-month return on equity of 82.06% and a net margin of 3.49%. Who are Organon & Co.'s major shareholders? Organon & Co.'s top institutional investors include State Street Corp (3.72%), Gabelli Funds LLC (0.51%), Public Sector Pension Investment Board (0.34%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.29%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Lynette Holzbaur, Kirke Weaver and Daniel Karp. View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Merck & Co., Inc. (MRK), Pfizer (PFE), AT&T (T), Verizon Communications (VZ), NVIDIA (NVDA), AbbVie (ABBV) and Bristol Myers Squibb (BMY). Company Calendar Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Last Earnings10/30/2026Record date for 12/10 Dividend11/09/2026Ex-Dividend for 12/10 Dividend11/09/2026Today11/13/2026Dividend Payable12/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OGN's financial health is in the Green zone, according to TradeSmith. OGN has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone(551) 430-6000FaxN/AEmployees10,000Year Founded2020Price Target and Rating Average Price Target for Organon & Co.$12.00 High Price Target$14.00 Low Price Target$8.00 Potential Upside/Downside-13.6%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.76 Trailing P/E Ratio18.28 Forward P/E Ratio4.05 P/E Growth1.28Net Income$187 million Net Margins3.49% Pretax Margin8.25% Return on Equity82.06% Return on Assets6.03% Debt Debt-to-Equity Ratio7.11 Current Ratio2.02 Quick Ratio1.51 Sales & Book Value Annual Sales$6.22 billion Price / Sales0.59 Cash Flow$5.79 per share Price / Cash Flow2.40 Book Value$4.54 per share Price / Book3.06Miscellaneous Outstanding Shares262,620,000Free Float258,368,000Market Cap$3.65 billion OptionableOptionable Beta1.53 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:OGN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OGN Stock Alerts